Cadila Healthcare has received final approval from the USFDA to market Tizanidine Hydrochloride Capsules, USP in strengths of 2mg, 4mg and 6mg. The drug, which is a muscle relaxant, will be produced at the SEZ facility located at Ahmedabad. The estimated sale for Tizanidine Hydrochloride Capsules is $58.6 million, as per IMS Jan 2017.
The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.